Dice Therapeutics, Inc.

Dice Therapeutics, Inc., formerly Dice Molecules Holdings LLC, is a biopharmaceutical company. The Company leverages its technology platform to build a pipeline of oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. It focuses on developing oral therapeutics against well-validated targets in immunology. Its platform, which it refers to as DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as systemic biologics. Its DELSCAPE platform to design and develop a pipeline of oral small molecule therapeutics against validated biologic targets to address chronic diseases in immunology and other therapeutic areas. It also develops a therapeutic candidate for immuno-oncology indications.